D4Z4 macrosatellite repeat region (D4Z4)

The D4Z4 macrosatellite repeat region is a large array of tandemly repeated DNA sequences (3.3 kb per unit) found primarily on chromosome 4q35 and chromosome 10q26, consisting of anywhere between 11 and 150 units in healthy individuals[2][4][7]. Each D4Z4 repeat contains a copy of the DUX4 retrogene, which encodes a double homeobox transcription factor expressed only in early embryonic stages or abnormally in FSHD[1][2][9]. Normally, the D4Z4 array is silent in somatic cells due to formation of heterochromatin with high DNA methylation and repressive histone modifications[3][4]. In FSHD1, contraction of the 4q35 D4Z4 array to fewer than 11 repeats (1–10) with a permissive haplotype (4qA) leads to local chromatin relaxation (euchromatinization), loss of epigenetic silencing, and aberrant activation of DUX4 expression in muscle, driving disease pathogenesis[2][4]. In FSHD2, similar DUX4 activation occurs secondary to mutations in epigenetic regulators such as SMCHD1, DNMT3B, and LRIF1, resulting in hypomethylation of the D4Z4 array[2][3]. The D4Z4 region also displays functional features of a chromatin insulator, mediated by binding of CTCF and A-type lamins, which is disrupted in disease states[5][6]. D4Z4 repeat number and DNA methylation status are used as biomarkers in molecular diagnosis of FSHD subtypes[2][7]. No current therapies directly target D4Z4; instead, therapeutic focus is on downstream gene (DUX4) repression or amelioration of muscle pathology[2][3][4]. In summary, D4Z4 is a macrosatellite DNA repeat region critical for chromatin organization and gene regulation, with a central role in the genetic and epigenetic etiology of facioscapulohumeral muscular dystrophy. It is not a traditional drug target like a receptor or enzyme, but its repeat structure, methylation status, and associated genes (notably DUX4) are essential for diagnostic and research applications in FSHD[2][4][6][7][9].

Other names

D4Z4 repeatD4Z4 arrayD4Z4 regionD4Z4 macrosatellite

Not applicable; this is not a direct drug target, but drugs affecting DNA methylation, chromatin structure, or DUX4 expression may influence disease pathogenesis